Cof C

MAY 0 2 2006

CASE PR/4-30970A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 72727191645

Express Mail Label Number

MAY 2 2006
Deute of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PATENT OF CUENOUD ET AL.

U.S. PATENT NO: 6,878,721

ISSUED: APRIL 12, 2005

FOR: BETA2-ADRENOCEPTOR AGONISTS

Certificate
MAY 0 5 2006

of Correction

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Request for Certificate of Correction under CFR § 1.322

Sir:

Pursuant to 37 CFR 1.322, it is hereby respectfully requested that a Certificate of Correction be issued for United States Patent 6,878,721 containing the corrections set forth on the appended Form PTO 1050.

Each of the errors is believed to be attributable to the Patent and Trademark Office as is evident from the following table:

Location and/or Error in Printed Patent	Location of Support in Specification or Amendment
Column 36, Line 48, allowed claim 41 (should be renumbered 15) was omitted and the remaining ciaims should be renumbered accordingly	Request for Amended Notice of Allowance, dated December 21, 2004 and Supplemental Notice of Allowability, dated February 14, 2005

Attached is a duplicate of Form PTO 1050, with at least one copy being suitable for printing.

Since the above errors are not ascribable to the patentees, no fee is believed to be necessitated by this Request for Certificate of Correction. However, in the event that a fee is required, the Commissioner is hereby authorized to charge said fee to Deposit Account No. 19-0134 in the name of Novartis.

Please send the Certificate of Correction to the address currently associated with Customer No. 001095, viz:

Novartis Corporate Intellectual Property One Health Plaza, 104/3 East Hanover, New Jersey 07936-1080

Respectfully submitted,

Attorney for Patentee

Reg. No. 47,666

Gregøry 🗘

Novartis

Corporate Intellectual Property One Health Plaza, 104/3

East Hanover, New Jersey 07936-1080

(862) 778-2614

Encls.: Form PTO 1050 (2)

Postcard

GCH:alg

Date: 5/2/06

- 2 -

Case: PR/4-30970A

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

6,878,721

DATED:

April 12, 2005

INVENTOR(S)

CUENOUD ET AL.

It is certified that there is/are an error(s) in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Columns 36 - 38,

Starting at Line 48 the claims should read:

-- 15. A compound according to claim 1, in which Ar is a group of formula II in which Y is carbon,

R⁸ is -NHR¹⁸ and -NHR¹⁸ and R⁹ together denote a group of formula -NH-CO-R²³- where R²³ is an alkenylene group,

R¹⁰ is -OR¹⁹, where R¹⁹ is as defined in claim 17,

X is alkyl,

p is 1, q is 1 and r is zero or 1.

16. A pharmaceutical composition comprising a compound according to claim 8, together with a pharmaceutically acceptable carrier.

17. A compound according to claim 1, in which Ar is a group of formula III

in which R29, R30 and R31 are each independently hydrogen or C1-C4-alkyl.

- 18. A compound according to claim 6, in which R4 and R7 are each hydrogen, and R5 and R6 are identical and are each C1-C4-alkyl.
- 19. A compound according to claim 7, in which R4 and R7 are each hydrogen, and R5 and R6 are identical and are each C1-C446. A method for treatment of premature labour pain comprising administering to a subject in need thereof an effective amount of a compound according to claim 17.
- 20. A method for treatment of premature labour pain comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.--

MAILING ADDRESS OF SENDER:

PATENT NO. 6,878,721

Gregory C. Houghton Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-2614

1

Case: PR/4-30970A

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO

6,878,721

DATED:

April 12, 2005

INVENTOR(S)

CUENOUD ET AL.

It is certified that there is/are an error(s) in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Columns 36 - 38,

Starting at Line 48 the claims should read:

-- 15. A compound according to claim 1, in which Ar is a group of formula II in which Y is carbon,

R⁸ is -NHR¹⁸ and -NHR¹⁸ and R⁹ together denote a group of formula -NH-CO-R²³- where R²³ is an alkenylene group,

R¹⁰ is -OR¹⁹, where R¹⁹ is as defined in claim 17,

X is alkyl,

p is 1, q is 1 and r is zero or 1.

16. A pharmaceutical composition comprising a compound according to claim 8, together with a pharmaceutically acceptable carrier.

17. A compound according to claim 1, in which Ar is a group of formula III

in which R29, R30 and R31 are each independently hydrogen or C1-C4-alkyl.

- 18. A compound according to claim 6, in which R4 and R7 are each hydrogen, and R5 and R6 are identical and are each C1-C4-alkyl.
- 19. A compound according to claim 7, in which R4 and R7 are each hydrogen, and R5 and R6 are identical and are each C1-C446. A method for treatment of premature labour pain comprising administering to a subject in need thereof an effective amount of a compound according to claim 17.
- 20. A method for treatment of premature labour pain comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.--

MAILING ADDRESS OF SENDER:

PATENT NO. 6,878,721

Gregory C. Houghton **Novartis** Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-2614

WW. & SOMP